Exenatide
Exenatide is an early GLP-1 receptor agonist derived from Gila monster venom; the community runs it mainly for weight management and blood sugar control, with smaller traction for cardiovascular health, and it is FDA-approved for Type 2 Diabetes. The modal daily dose is 10 mcg, taken continuously without cycling, though captured user reports span 5 mcg to 2 mg and timing varies. The off-label evidence base is thinner than the discourse suggests, and most exploratory indications lack posted trial results.
Research Evidence
Evidence shape
Exenatide has high-tier evidence, anchored by Phase 3 trials in type 2 diabetes and a narrower set of obesity trials. Across 92 mapped indications, only 20 have posted results; the core confidence comes from 48 blinded trials with outcomes on record and 110 distinct sponsors. The remaining 66 are thin or exploratory, 58 are single-trial long-tail indications, and several areas—including alcohol use disorder and septic shock—carry no trial data at all.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
No live vendor pricing captured for this peptide yet.
Dosing & Protocol
How Exenatide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- twice daily or once weekly
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
230 completed trials identified; trial dosing not reliably extracted from registry data.
No structured protocol details captured for this tier yet.
- Frequency
- unspecified
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Community discussions around exenatide (Byetta/Bydureon) reflect its use for blood sugar control and weight management. For blood sugar, 6 of 6 reports were positive. For weight management, 2 of 4 reports were positive, with 2 negative. Specific dose hints are not consistently provided in posts, but anecdotal use aligns with clinical forms (e.g., 5-10 mcg BID for Byetta, 2 mg QW for Bydureon).
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including exenatide. Discontinue if pancreatitis is suspected. Never share an exenatide injection pen between patients, even if the needle is changed.
- • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may…
- • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
- • Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. Exenatide is not recommended in patients with severe gastroparesis.
- • Immunogenicity : Patients may develop antibodies to exenatide. If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy.
- • Hypersensitivity : Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue exenatide and promptly seek medical advice.
- • Drug-induced Immune-mediated Thrombocytopenia : Serious bleeding which may be fatal has been reported. Discontinue exenatide promptly and avoid re-exposure to exenatide.
- • Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.
- • Exenatide injection is contraindicated in
- • patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with ex…
- • Table 6: Clinically Relevant Interactions with Exenatide Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglyc…
- • Warfarin: Post-marketing reports of increased INR sometimes associated with bleeding. Monitor INR frequently until stable upon initiation or alteration of exenatide therapy. (7)
Peptide feedback
0 forum repliesLive community discussion for Exenatide, shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.